I was surprised to find out that Procognia can do heparins and of course this could add more weight to Teva's ANDA but Momenta was focused on heparins for years and I think they have the advantage there.
After yesterday's event this may have a new meaning if TEVA did use or Procognia's technology to strengthen their generic Lovenox ANDA. Can they still do it now? (Is it possible to add new data after submitting the ANDA?)
On a side note, Procognia's advantage over Momenta's is in biological systems where time to decision is crucial like when doing clone selection (MNTA's tech requires more time and preparations).
Market Data 
Markets 
AI
